Cerus Corporation (CERS) Stock Analysis

Cerus Corporation (CERS) is a publicly traded company in the HEALTHCARE sector. It trades at $2.70, carries a market capitalization of $609.12M. This page summarizes the public market data, fundamentals, and frequently asked questions for CERS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL DEVICES

Exchange: NASDAQ

Key Metrics

• Price: $2.70
• Market Cap: $609.12M
• EPS: $-0.05
• 52-Week High: $3.15
• 52-Week Low: $1.15

Market Sentiment

Cerus Corporation currently has a Neutral sentiment score of -0.00.

About Cerus Corporation

Cerus Corporation (CERS) is a pioneering biomedical products company focused on improving blood safety through its groundbreaking INTERCEPT Blood System, designed to inactivate pathogens in blood components. Headquartered in Concord, California, Cerus employs state-of-the-art technology to meet the critical demands of transfusion medicine, ensuring enhanced patient safety. With a robust and expanding portfolio, the company is strategically positioned to capitalize on the global need for safe ...

GNG Research Analysis

GNG Research scores Cerus Corporation (CERS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CERS.

Frequently Asked Questions

Does CERS pay dividends?

Cerus Corporation (CERS) does not currently pay a regular dividend.

What is CERS's market cap?

Cerus Corporation (CERS) has a market capitalization of $609.12M with a current stock price of $2.70.